“…The study demonstrated that the first two were more sensitive than ACR 97 to the population under study. Lobo Prat [ 22 ] also compared EULAR/ACR 2019 and SLICC 2012 without documenting differences in sensitivity with respect to patients with long disease duration and had results similar to those in studies by Vrancianu [ 23 ] and Duarte-Garcia [ 24 ]. The Johnson et al [ 25 ] study included patients with Hispanic ancestry and got results that contrast with ours given that, for them, the EULAR/ACR 2019 criteria were better on patients with early disease in terms of sensitivity.…”